EPIC: an effective low toxicity regimen for relapsing lymphoma

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Relapsed or resistant lymphoma presents a significant clinical challenge, necessitating effective treatment strategies.
• Current treatment options for recurrent lymphoma often involve significant toxicity and morbidity.
• Identifying predictive factors for treatment response is crucial for optimizing patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of the Etoposide, Prednisolone, Ifosfamide, and Cisplatin (EPIC) regimen in patients with relapsed or resistant lymphoma.
• To identify clinical and biological factors associated with treatment response and survival in this patient population.

Main Methods:

• A prospective study involving 40 patients with relapsed or resistant lymphoma treated with the EPIC regimen.
• Response assessment included complete response (CR) and overall response (OR).
• Statistical analysis was performed to identify factors associated with response and survival, including multivariate analysis.

Main Results:

• The EPIC regimen achieved a complete response in 28% and an overall response of 58% of patients.
• Bulky disease and B symptoms were identified as independent adverse prognostic factors for response and survival.
• The regimen was generally well-tolerated, with myelosuppression (leukopenia and thrombocytopenia) being the most common toxicity. No treatment-related deaths occurred.

Conclusions:

• The EPIC regimen demonstrates significant activity in relapsed or resistant lymphoma, comparable to other cisplatin-based regimens.
• The treatment is associated with lower treatment-related morbidity and mortality compared to existing therapies.
• The presence of bulky disease and B symptoms are critical indicators for poorer outcomes, guiding treatment decisions.